From China With IO: Lilly Bets $1bn+ To Take Innovent Drug Global
Chinese Firm To Internationalize Via Wider Partnership
Lilly is acquiring exclusive global rights to a Chinese domestically developed immuno-oncology drug in one of the year’s biggest commercial deals in the country.
